Literature DB >> 27967213

Could NLRP3-Inflammasome Be a Cardiovascular Risk Biomarker in Acute Myocardial Infarction Patients?

Pedro Bullón1, Francisco J Cano-García2, Elísabet Alcocer-Gómez1, Alfonso Varela-López3, Lourdes Roman-Malo1, Rafael J Ruiz-Salmerón4, José L Quiles3, José M Navarro-Pando5, Maurizio Battino6, Jesús Ruiz-Cabello7,8, Luis J Jiménez-Borreguero9,10, Mario D Cordero1.   

Abstract

Conventional cardiovascular risk factors (CVRFs) are accepted to identify asymptomatic individuals with high risk of acute myocardial infarction (AMI). However, AMI affects many patients previously classified at low risk. New biomarkers are needed to improve risk prediction. We propose to evaluate the NLRP3-inflammasome complex as a potential conventional cardiovascular risk (CVR) indicator in healthy males and post-AMI patients and compare both groups by known CVRFs. We included 109 men with no history of cardiovascular disease (controls) and 150 AMI patients attending a cardiac rehabilitation program. AMI patients had higher mean of body mass index (BMI) and waist circumference than the controls. However, high percentages of the controls had a high BMI and a waist circumference >95 cm. The controls also had higher systolic blood pressure (p > 0.001), total and low-density lipoprotein cholesterol, dietary nutrient, and calorific intake. Fuster BEWAT score (FBS) correlated more closely than Framingham risk score (FRS) with most CVRF, groups. However, only the FBS showed a correlation with inflammasome cytokine interleukin 1β (IL-1β). Several CVRFs were significantly better in AMI patients; however, this group also had higher mRNA expression of the inflammasome gene NLRP3 and lower expression of the autophagy gene MAP-LC3. The controls had high levels of CVRF, probably reflecting unhealthy lifestyle. FBS reflects the efficiency of strategies to induce lifestyle changes such as cardiac rehabilitation programs, and could provide a sensitive evaluation CVR. These results lead to the hypothesis that NLRP3-inflammasome and associated IL-1β release have potential as CVR biomarkers, particularly in post-AMI patients with otherwise low risk scores. Antioxid. Redox Signal. 27, 269-275.

Entities:  

Keywords:  Framingham risk score; Fuster BEWAT score; NLRP3–inflammasome complex; cardiovascular risk factors

Mesh:

Substances:

Year:  2017        PMID: 27967213     DOI: 10.1089/ars.2016.6970

Source DB:  PubMed          Journal:  Antioxid Redox Signal        ISSN: 1523-0864            Impact factor:   8.401


  12 in total

1.  Cadmium induces renal inflammation by activating the NLRP3 inflammasome through ROS/MAPK/NF-κB pathway in vitro and in vivo.

Authors:  Ziyin Li; Huiqin Chi; Wei Zhu; Guangyu Yang; Jia Song; Lijun Mo; Yitian Zhang; Yudi Deng; Feifei Xu; Jiani Yang; Zhini He; Xingfen Yang
Journal:  Arch Toxicol       Date:  2021-09-12       Impact factor: 5.153

2.  Blockade of the NLRP3 inflammasome improves metabolic health and lifespan in obese mice.

Authors:  Diego Cañadas-Lozano; Fabiola Marín-Aguilar; Beatriz Castejón-Vega; Bernhard Ryffel; José M Navarro-Pando; Jesús Ruiz-Cabello; Elísabet Alcocer-Gómez; Pedro Bullón; Mario D Cordero
Journal:  Geroscience       Date:  2020-01-23       Impact factor: 7.713

Review 3.  COVID-19-associated cardiovascular morbidity in older adults: a position paper from the Italian Society of Cardiovascular Researches.

Authors:  F Moccia; A Gerbino; V Lionetti; M Miragoli; L M Munaron; P Pagliaro; T Pasqua; C Penna; C Rocca; M Samaja; T Angelone
Journal:  Geroscience       Date:  2020-05-20       Impact factor: 7.713

4.  Kanglexin, a novel anthraquinone compound, protects against myocardial ischemic injury in mice by suppressing NLRP3 and pyroptosis.

Authors:  Yu Bian; Xin Li; Ping Pang; Xue-Ling Hu; Shu-Ting Yu; Yi-Ning Liu; Xin Li; Ning Wang; Jin-Hui Wang; Wei Xiao; Wei-Jie Du; Bao-Feng Yang
Journal:  Acta Pharmacol Sin       Date:  2019-10-23       Impact factor: 6.150

5.  Inhibition of the NLRP3 inflammasome prevents ovarian aging.

Authors:  José M Navarro-Pando; Elísabet Alcocer-Gómez; Beatriz Castejón-Vega; Elena Navarro-Villarán; Mónica Condés-Hervás; María Mundi-Roldan; Jordi Muntané; Antonio J Pérez-Pulido; Pedro Bullon; Chun Wang; Hal M Hoffman; Alberto Sanz; Gabriel Mbalaviele; Bernhard Ryffel; Mario D Cordero
Journal:  Sci Adv       Date:  2021-01-01       Impact factor: 14.136

6.  Resveratrol improves cardiac function and left ventricular fibrosis after myocardial infarction in rats by inhibiting NLRP3 inflammasome activity and the TGF-β1/SMAD2 signaling pathway.

Authors:  Jinjin Jiang; Xiuping Gu; Huifeng Wang; Shibin Ding
Journal:  PeerJ       Date:  2021-05-28       Impact factor: 2.984

7.  NLRP3-inflammasome inhibition prevents high fat and high sugar diets-induced heart damage through autophagy induction.

Authors:  Luís E Pavillard; Diego Cañadas-Lozano; Elísabet Alcocer-Gómez; Fabiola Marín-Aguilar; Sheila Pereira; Avril A B Robertson; Jordi Muntané; Bernhard Ryffel; Matthew A Cooper; José L Quiles; Pedro Bullón; Jesús Ruiz-Cabello; Mario D Cordero
Journal:  Oncotarget       Date:  2017-09-08

Review 8.  Protein and Mitochondria Quality Control Mechanisms and Cardiac Aging.

Authors:  Rajeshwary Ghosh; Vishaka Vinod; J David Symons; Sihem Boudina
Journal:  Cells       Date:  2020-04-10       Impact factor: 6.600

9.  NLRP3 inflammasome suppression improves longevity and prevents cardiac aging in male mice.

Authors:  Fabiola Marín-Aguilar; Ana V Lechuga-Vieco; Elísabet Alcocer-Gómez; Beatriz Castejón-Vega; Javier Lucas; Carlos Garrido; Alejandro Peralta-Garcia; Antonio J Pérez-Pulido; Alfonso Varela-López; José L Quiles; Bernhard Ryffel; Ignacio Flores; Pedro Bullón; Jesús Ruiz-Cabello; Mario D Cordero
Journal:  Aging Cell       Date:  2019-10-18       Impact factor: 9.304

10.  Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis.

Authors:  Stevan D Stojanović; Jan Fiedler; Johann Bauersachs; Thomas Thum; Daniel G Sedding
Journal:  Eur Heart J       Date:  2020-08-14       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.